Accelerating self-administration and homecare: SCHOTT Pharma launches large-volume prefillable glass syringe

The global large-volume injectors market is expected to witness substantial growth over the next decade, driven by factors such as the rising prevalence of chronic diseases, a shift towards homecare, and technological advancements in injector devices. This progress is accompanied by a transition from intravenous to subcutaneous drug administration, which offers cost benefits to healthcare systems and ensures safe and comfortable home injections for numerous patients, albeit requiring drug reformulation efforts from pharmaceutical companies and the development of new large-volume delivery solutions.

Addressing this market demand, SCHOTT Pharma is expanding its product range with large-volume solutions. The new 5.5 ml large-volume prefillable stake-needle glass syringe supplements the syriQ BioPure^® platform and is designed to store and deliver large volumes of complex biologics and highly sensitive drugs. Manufactured using specialized technology, these syringes maintain ultra-low tungsten levels, minimizing drug-container interaction risks throughout the product’s shelf life. Designed for optimal functionality, they ensure treatment continuity at home and efficiency while seamlessly integrating with autoinjectors, offering safe and simple drug administration for patients.

SCHOTT Pharma’s syriQ BioPure^® 5.5 ml glass syringe is compatible with Datwyler’s latest plunger and Ypsomed's YpsoMate^® 5.5 ml large-volume autoinjector. “By integrating SCHOTT Pharma's new large-volume glass syringe into our YpsoMate^® 5.5 autoinjector, Ypsomed is driving the move into the large-volume segment. This step underscores our strong long-term partnership with SCHOTT Pharma and our dedication to swiftly bringing innovative, patient-friendly injection systems to market. With this collaboration, we actively enable clinical studies and accelerate the introduction of various large-volume therapies to the market,” says Ulrike Bauer, Chief Business Officer (CBO) from Ypsomed.

With this launch, SCHOTT Pharma continues to advance its mission of enhancing patient care and facilitating the widespread adoption of homecare solutions worldwide.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com